Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:
“JCOG1019 trial compared 8 doses of BCG vs. no treatment in HG T1 bladder cancer patients with pT0 reTURBT.
5-year RFS: 87% (BCG) vs. 82% (no treatment). Metastasis rates: 15% (BCG) vs. 21% (no treatment).
My Conclusion: 8 doses of BCG =insufficient; maintenance is critical.”
